A Greek Observational Study on Relapse Rate and Sustained Virological Response in Naive CHC [chronic hepatitis C] Patients, Treated With Pegylated Interferon Alpha-2b and Ribavirin in Daily Clinical Practice.
Phase of Trial: Phase IV
Latest Information Update: 01 Jan 2014
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
- 07 Jun 2017 Biomarkers information updated
- 04 Oct 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 04 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.